Form 4: TELA Bio COO/CFO Cuca Reports Significant Equity Grants

TELA Bio's COO and CFO, Roberto Cuca, reported the acquisition of 57,000 restricted stock units and 85,000 stock options, alongside tax-related share dispositions.

Summary

• Roberto Cuca, COO and CFO of TELA Bio, Inc., reported transactions involving company equity.
• On February 20, 2026, Cuca acquired 57,000 restricted stock units (RSUs) which will vest in four equal annual installments beginning February 20, 2027, subject to continuous service.
• Also on February 20, 2026, Cuca acquired 85,000 stock options with an exercise price of $0.717. These options vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 calendar months, subject to continuous service.
• Following these acquisitions, Cuca's beneficial ownership of common stock was 267,391 shares, which includes 1,079 shares acquired under the Company's employee stock purchase plan on July 31, 2025, and January 30, 2026.
• On February 21, 2026, 4,780 shares were disposed of at $0.7174 to satisfy applicable withholding taxes upon RSU vesting, reducing beneficial ownership to 262,611 shares.
• On February 23, 2026, an additional 5,234 shares were disposed of at $0.766 for tax withholding purposes, resulting in a beneficial ownership of 257,377 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects significant equity grants to a key executive, aligning management's long-term interests with shareholder value, which is a strong indicator of confidence in future performance.

Positives

• Grant of 57,000 restricted stock units (RSUs) to the COO and CFO, aligning management's interests with long-term shareholder value.
• Grant of 85,000 stock options to the COO and CFO, providing an incentive for future performance and stock price appreciation.
• Continued participation in the Company's employee stock purchase plan, indicating ongoing commitment from the COO and CFO.

Negatives

• Disposition of 4,780 shares at $0.7174 and 5,234 shares at $0.766 to cover tax withholding obligations, which represents a reduction in direct share ownership.

Risks

• NA

Future Outlook

The filing indicates future vesting schedules for restricted stock units and stock options granted to the COO and CFO, extending through February 2027 for initial vesting and up to February 2036 for option expiration, contingent on continuous service.

Management Comments

• NA

Industry Context

StockSavvy.ai notes that equity grants to key executives like the COO and CFO are a standard practice in the biotechnology and medical device industry to incentivize long-term performance and align executive interests with shareholder value. Such grants are common for retaining talent and motivating strategic growth initiatives.

Comparison to Industry Standards

• Equity compensation packages for senior executives in the medical technology sector typically include a mix of restricted stock units and stock options, often with multi-year vesting schedules to ensure retention and performance alignment.
• For example, similar grants are observed at companies like Stryker or Medtronic, where executive compensation is heavily tied to long-term equity performance.
• The vesting schedule of 25% after one year and then monthly over 36 months for options, and four equal annual installments for RSUs, is a common structure designed to encourage sustained commitment and performance.

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The equity grants align the COO and CFO's interests with shareholders, potentially leading to more focused long-term value creation.
• Employees: The filing highlights the company's use of equity compensation, which can be a positive signal for employee retention and motivation, especially for key personnel.

Next Steps

• Continued vesting of 57,000 restricted stock units in four equal annual installments beginning February 20, 2027.
• Continued vesting of 85,000 stock options, with 25% vesting on February 20, 2027, and the remainder vesting monthly over 36 calendar months.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants and subsequent tax-related share dispositions. While the grants align executive interests with long-term shareholder value, the transactions themselves do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

TELA Bio, TELA, Form 4, Insider Trading, Roberto Cuca, COO, CFO, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Beneficial Ownership, Executive Compensation